HMGB1 and prostate carcinoma: When we administered glycyrrhizin or other HMGB1-neutralizing antibodies to desmoplasma-resistant prostate cancer cells that had developed resistance to paclitaxel, and then treated the cells again with paclitaxel, their sensitivity to paclitaxel was significantly restored (76).